By the end of 2022, the market for Competent Cells is anticipated to reach US$ 2.1 billion, growing at a double-digit rate of 11.1% CAGR (2022-2032). By 2032, the market’s sales are projected to be worth $5.9 billion USD. Chemically competent cells held the market’s top spot in terms of product type in 2021, with a share of about 67.8%.
The latest research study published by Future Market Insights (FMI) projects the global competent cells market to register an impressive 8.1% CAGR throughout the forecast period 2017 to 2022. The global market for competent cells is estimated to exceed US$ 2,000 Mn in revenues by 2022-end.
Competent Cells Available in the Market in Ready-to-use Formats
Preparations of competent cells, along with other methods of transformation, have been continuously improvised, since the development of E. coli’s artificial transformation with the help of electroporation and chemicals. Currently, various competent cells are available in the market in ready-to-use formats for propagating cloned plasmids in the experiments of molecular biology. These competent cells are prepared for different transformation procedures, genotypes, packaging, and transformation efficiencies.
With the advent of new technologies, several advancements have been witnessed in the molecular cloning research. Over the past few years, the recombinant proteins and molecular cloned products have experienced a robust commercial demand, thereby driving adoption of competent cells. However, adoption of competent cells is witnessing strong barriers on the back of increasing consolidation of the market, and huge cost of kits related to competent cells.
Unlock a visually enticing sample report with compelling graphs and charts. @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5061
Academic Research Institutes to Remain Largest End-users of Competent Cells
Academic research institutes are anticipated to remain the largest end-users of competent cells throughout the forecast period. Sales of competent cells in academic research institutes are projected to exhibit an impressive expansion to account for nearly half revenue share of the market during 2017 to 2022. However, sales of competent cells in pharmaceutical & biotechnology companies are expected to register the fastest expansion through 2022. Contract research organisations are expected to be the least lucrative end-users of competent cells in the global market.
Competent cells are expected to find the largest application in cloning during 2017 to 2022. Governments across the globe are providing tremendous support and funding for research and development activities associated with cloning. Revenues from sales of competent cells for application in cloning are estimated to account for over half revenue share of the market during the forecast period. Sales of competent cells for application in protein expression are expected to register the highest CAGR through 2022.
Digging deeper: Examining the core assumptions of the study. Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-5061
North America will Continue to be Largest Market for Competent Cells
In terms of revenues, North America is anticipated to remain the largest market for competent cells, with sales estimated to exceed US$ 750 Mn in revenues by 2022-end. Huge investments in research and development activities associated with competent cells is driving the market in North America. In addition, the market in Europe is estimated to create an absolute $ opportunity of nearly US$ 200 Mn between 2017 and 2022.
On the basis of product type, although chemically competent cells will continue to be sought-after in the market, sales of electrocompetent cells are projected to register a relatively faster expansion through 2022. Growing demand for electrocompetent cells can be mainly attributed to their provision of high transformation efficiencies, making them suitable for several molecular biology applications, for example – construction of gene banks, or, generation of cDNA libraries. Revenues from sales of electrocompetent cells are projected to account for nearly one-third share of the market over the forecast period.
Leading Market Players Focusing on Increasing their Product Portfolio
Global leading players in the competent cells market are focusing on increasing their product folio, in a bid to gain a competitive edge in the market. Key players listed in FMI’s report on the global competent cells market include:
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Genescript Biotech Corporation
- Illumina Inc.
- Merck & Co. Inc.
- New England Biolabs Inc.
- OriGene Technologies Inc.
- QIAGEN N.V.
- Thermo Fischer Scientific Inc.
- Zymo Research Corporation.
Make your mark with a meticulously designed and customized report.@ https://www.futuremarketinsights.com/customization-available/rep-gb-16916
Market Taxonomy Region
- North America
- Latin America
- Europe
- Japan
- APEJ
- MEA
Product Type
- Chemically Competent Cells
- Electrocompetent Cells
End User
- Academic Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
Application
- Cloning
- Protein Expression
- Other Applications
Explore Wide-ranging Coverage of FMI’s Healthcare Landscape:
Amniotic Membranes Market: The global amniotic membranes market size is likely to touch a valuation of around US$ 1.4 Bn in 2022. Further, with rising adoption of amniotic membranes for various purposes in ophthalmology, the total sales of amniotic membranes are slated to grow at an impressive CAGR of 9.0% between 2022 and 2028, totalling over US$ 2.3 Bn by the end of 2028.
Digital Radiography Detectors Market: The digital radiography detectors market is valued at US$ 2.13 Bn in 2022. The market is advancing at an average pace with a CAGR of 6.1% through 2026 to reach a valuation of US$ 2.7 Bn. The worldwide market for digital radiography detectors is highly concentrated, with large competitors such as Varex Imaging Corporation and Trixell accounting for about 47% of the market share.
Sepsis Diagnostics Market: The global sepsis diagnostics market is expected to record a CAGR of 8.1% between 2023 and 2033. In 2023, the market is estimated to be valued at US$ 561.2 million. The valuation is expected to cross US$ 1.2 billion by 2033
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube